Home
Resource
Biomarkers of response to immune checkpoint therapy
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(16.05 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Panda, Anshuman. Biomarkers of response to immune checkpoint therapy. Retrieved from https://doi.org/doi:10.7282/T3CF9T9C

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleBiomarkers of response to immune checkpoint therapy
NamePanda, Anshuman (author); Bhanot, Gyan (chair); Khiabanian, Hossein (internal member); Sengupta, Anirvan (internal member); Bartynski, Robert (internal member); Ganesan, Shridar (outside member); Rutgers University; School of Graduate Studies
Date Created2018
Other Date2018-01 (degree)
SubjectPhysics and Astronomy, Cancer--Treatment
Extent1 online resource (viii, 64 p. : ill.)
DescriptionImmune checkpoint therapy leads to durable objective response in a subset of patients with metastatic cancer in many different cancer types, but the mechanisms and biomarkers of response to immune checkpoint therapy is not fully understood. Through pan-cancer analysis of the Cancer Genome Atlas, I have so far identified 2 types of predictors of immune activation and checkpoint pathway upregulation in a total of 10 solid cancer types (skin melanoma, lung adenocarcinoma, colon, endometrial, gastric, cervical, ER+ HER2− breast, bladder, clear-cell kidney, and head-neck squamous-cell cancer): (1) hyper-mutation in tumor due to DNA proofreading defect (Chapter 2) or some other etiologies (Chapter 3), and (2) expression of exogenous (Chapter 4) or endogenous (Chapter 5) viral RNA in tumor. I also validated these predictors as biomarkers of response to immune checkpoint therapy in some of the above 10 cancer types where I had access to good quality data, using published datasets of patients treated with immune checkpoint therapy for retrospective validation, and de-identified data of patients treated with immune checkpoint therapy at the Rutgers Cancer Institute of New Jersey and the Vanderbilt Ingram Cancer Center for prospective validation.
NotePh.D.
NoteIncludes bibliographical references
Noteby Anshuman Panda
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3CF9T9C
Languageeng
CollectionSchool of Graduate Studies Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024